Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina

被引:2
|
作者
Trogdon, Justin G. [1 ]
Shafer, Paul [1 ]
Lindsay, Brianna [2 ]
Coyne-Beasley, Tamera [3 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1101 McGavran Greenberg Hall,Campus Box 7411, Chapel Hill, NC 27599 USA
[2] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA
[3] Univ N Carolina, Dept Pediat, 260 MacNider Bldg,Campus Box 7220, Chapel Hill, NC 27599 USA
关键词
Human papillomavirus; Vaccination; Interrupted time series; AGED; 13-17; YEARS; COST-EFFECTIVENESS; UNITED-STATES; ADVISORY-COMMITTEE; HPV VACCINATION; CERVICAL-CANCER; POLIO ENDGAME; RECOMMENDATIONS; HEALTH;
D O I
10.1016/j.vaccine.2018.01.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The objective of this study was to evaluate the impact of introduction of 9vHPV vaccine on HPV vaccination uptake (doses per capita) and initiation (>= 1 doses), completion (>= 3 doses) and compliance (>= 3 doses within 12 months) by adolescents. Methods: We used a retrospective cohort analysis using North Carolina Immunization Registry (NCIR) data from January 2008 through October 2016. The sample included Vaccines for Children eligible adolescents aged 9 to 17 years in 2016, for whom the NCIR contains complete vaccination history. We applied an interrupted time series design to measure associations between ZIP Code Tabulation Area (ZCTA)-level HPV vaccination outcomes over time with the introduction of 9vHPV in North Carolina (NC) in July 2015. Results: Each outcome displayed a linear upward trend over time with large seasonal spikes near August of each year, corresponding to the time when adolescents often receive other vaccines required for school entry. After accounting for these underlying trends, introduction of 9vHPV was not associated with a change in publicly funded HPV vaccination rates in NC. Conclusions: Our results indicate that 9vHPV substituted for 4vHPV in the first year after release in NC, but the release of 9vHPV was not associated with an overall change in HPV vaccination. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1304 / 1309
页数:6
相关论文
共 50 条
  • [41] Assessing Barriers to Human Papillomavirus (HPV) Vaccination in At-Risk Rural Communities of Western North Carolina, United States
    McNeil, Candice J.
    Barr, Breona
    Munawar, Iqra
    DeWitt, Michael E.
    Myers, Jenny Snow
    Shetty, Avinash K.
    VACCINES, 2023, 11 (12)
  • [42] Real-world safety profile of the 9-valent human papillomavirus vaccine: A study in Zhejiang, China from 2019 to 2021
    Chen, Fuxing
    Pan, Xuejiao
    Liang, Hui
    Shen, Lingzhi
    Wang, Ying
    Chen, Yaping
    Lv, Huakun
    Hu, Yu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (07)
  • [43] Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis
    Laprise, Jean-Francois
    Markowitz, Lauri E.
    Chesson, Harrell W.
    Drolet, Melanie
    Brisson, Marc
    JOURNAL OF INFECTIOUS DISEASES, 2016, 214 (05): : 685 - 688
  • [44] The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia
    Mahumud, Rashidul Alam
    Alam, Khorshed
    Dunn, Jeff
    Gow, Jeff
    PLOS ONE, 2019, 14 (10):
  • [45] Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study
    Rahman, Shams
    Campbell, Christine M. Pierce
    Rollison, Dana E.
    Wang, Wei
    Waterboer, Tim
    Michel, Angelika
    Pawlita, Michael
    Villa, Luisa L.
    Lazcano Ponce, Eduardo
    Borenstein, Amy R.
    Giuliano, Anna R.
    PLOS ONE, 2016, 11 (11):
  • [46] Towards the elimination of cervical cancer: HPV epidemiology, real-world experiences and the potential impact of the 9-valent HPV vaccine
    Prandi, Gian Marco
    Cocchio, Silvia
    Fonzo, Marco
    Furlan, Patrizia
    Nicoletti, Michele
    Baldo, Vincenzo
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (05) : 1068 - 1078
  • [47] Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S
    Hirth, Jacqueline
    McGrath, Christine J.
    Kuo, Yong-Fang
    Rupp, Richard E.
    Starkey, Jonathan M.
    Berenson, Abbey B.
    VACCINE, 2018, 36 (50) : 7682 - 7688
  • [48] Coverage of human papillomavirus vaccination during the first year of its introduction in Spain
    Limia, A.
    Pachon, I.
    EUROSURVEILLANCE, 2011, 16 (21): : 12 - 15
  • [49] Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
    Garland, Suzanne M.
    Anagani, Manjula
    Bhatla, Neerja
    Chatterjee, Sukanta
    Lalwani, Sanjay
    Ross, Cecil
    Group, Thomas
    Lin, Jianxin
    Luxembourg, Alain
    Walia, Anuj
    Tu, Yingmei
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [50] Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men
    Giuliano, Anna R.
    Wilkin, Timothy
    Bautista, Oliver M.
    Cheon, Kyeongmi
    Connor, Laurie
    Dubey, Sheri
    Group, Thomas
    Luxembourg, Alain
    Rawat, Sonali
    Shaw, Anita
    Velicer, Christine
    Vendetti, Neika
    Tu, Yingmei
    CONTEMPORARY CLINICAL TRIALS, 2022, 115